spacer
home > white papers > Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014 - Synergy Research Group
WHITE PAPERS
logo_Synergy_Re.JPG

Synergy Research Group

phone +7 495 600 4445
email request@synrg-pharm.com
web http://www.synrg-pharm.com
email 11, 4-Magistralnaya Ul., 123007 Moscow, Russia

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible.

In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>


White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>


Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement